# Chemicals - Speciality — company-by-company sector analysis

> Chemicals - Speciality: Jubilant Agri & Consumer Products Ltd owns the largest revenue base; Anlon Healthcare Ltd has the fastest current growth.

Sector Alpha — machine-written from the numbers. Data as of 2026-07-29. Not investment advice.

## Bottom line

Chemicals - Speciality has outperformed NIFTY 500 by 74.2% over 52 weeks and 25% over 13 weeks. 2 of 3 covered companies beat NIFTY on Mansfield relative strength, while 0 of 1 beat the sector itself. Jubilant Agri & Consumer Products Ltd leads with revenue of ₹1,891 crore, based on 5 of 5 comparable companies through Mar 2026.

### Is the Chemicals - Speciality sector outperforming NIFTY 500?

Chemicals - Speciality has outperformed NIFTY 500 by 74.2% over 52 weeks and 25% over 13 weeks. 2 of 3 covered companies beat NIFTY on Mansfield relative strength, while 0 of 1 beat the sector itself.

### Which Chemicals - Speciality company is largest by revenue?

Jubilant Agri & Consumer Products Ltd leads with revenue of ₹1,891 crore, based on 5 of 5 comparable companies through Mar 2026.

### Which Chemicals - Speciality company is growing fastest?

Anlon Healthcare Ltd has the fastest current revenue growth at 43.3%, across 4 of 5 comparable companies.

### Which Chemicals - Speciality company has the strongest 4-Factor Sector Score?

Chembond Chemicals Ltd ranks first at 62.2/100 with 62% evidence confidence. The score prioritizes research; it is not a buy recommendation.

### Which Chemicals - Speciality company reports the most CAPEX?

Sudeep Pharma Ltd reports the largest latest CAPEX at ₹14 crore, with 2 of 5 companies comparable.

### Which Chemicals - Speciality company has the least gross debt?

Chembond Chemicals Ltd has the lowest comparable gross debt at ₹0 crore. Sudeep Pharma Ltd has the highest at ₹150 crore.

### Which Chemicals - Speciality company has the lowest comparable PEG?

Jubilant Agri & Consumer Products Ltd has the lowest comparable Guarded PEG at 0.79, among 2 of 5 companies that pass the metric’s comparability rules.

### How much history does this Chemicals - Speciality comparison include?

The page compares up to 20 reported quarters per company for fundamentals, CAPEX, debt and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

### How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

## Sector relative strength

Chemicals - Speciality has outperformed NIFTY 500 by 74.2% over the last 52 weeks. Over 13 weeks the gap is a lead of 25%. 2 of 3 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Jubilant Agri & Consumer Products Ltd is the strongest against the sector itself at -29%.

13-week sector return versus NIFTY 500: 25%
52-week sector return versus NIFTY 500: 74%
Stocks leading NIFTY: 2/3
Stocks leading sector: 0/1

Central tension: The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Companies: 5
Combined market value: ₹14.8K Cr

## 4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

1. Chembond Chemicals Ltd (CHEMBONDCH): 62/100 — Mixed-positive evidence; evidence 62%
   - Growth & earnings 22.7/35 | Capital efficiency 17.0/25 | Valuation 10.0/20 | Relative strength 12.5/20
   - Exact sum: 22.7 + 17 + 10 + 12.5 = 62.2
   - Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2. Jubilant Agri & Consumer Products Ltd (JUBLCPL): 62/100 — Mixed-positive evidence; evidence 80%
   - Growth & earnings 26.6/35 | Capital efficiency 17.7/25 | Valuation 14.8/20 | Relative strength 3.0/20
   - Exact sum: 26.6 + 17.7 + 14.8 + 3 = 62.1
   - Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -29% and the one-year return is -5.9%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
3. Anlon Healthcare Ltd (AHCL): 52/100 — Thin evidence · provisional; evidence 53%
   - Growth & earnings 19.7/35 | Capital efficiency 12.2/25 | Valuation 10.0/20 | Relative strength 10.0/20
   - Exact sum: 19.7 + 12.2 + 10 + 10 = 51.9
   - Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4. Sudeep Pharma Ltd (SUDEEPPHRM): 47/100 — Mixed-negative evidence; evidence 63%
   - Growth & earnings 14.1/35 | Capital efficiency 17.5/25 | Valuation 5.0/20 | Relative strength 10.0/20
   - Exact sum: 14.1 + 17.5 + 5 + 10 = 46.6
   - Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
5. Innovassynth Technologies (India) Ltd (533315): 47/100 — Thin evidence · provisional; evidence 23%
   - Growth & earnings 15.5/35 | Capital efficiency 8.8/25 | Valuation 10.0/20 | Relative strength 12.5/20
   - Exact sum: 15.5 + 8.8 + 10 + 12.5 = 46.8
   - Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

## Revenue Scale & Growth Durability

What the numbers say: Jubilant Agri & Consumer Products Ltd is the scale leader at ₹1,891 crore, 194.5% ahead of Sudeep Pharma Ltd. Anlon Healthcare Ltd's growth is 43.3% from a ₹173 crore base, with 8 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

Investor read: Jubilant Agri & Consumer Products Ltd is the scale benchmark; Anlon Healthcare Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Jubilant Agri & Consumer Products Ltd's growth falls below Anlon Healthcare Ltd's for two consecutive comparable reports while operating margin also compresses.

Evidence: Jubilant Agri & Consumer Products Ltd · ₹1,891 crore | 194.5% versus #2 · Sudeep Pharma Ltd | 6/6 recent comparable periods | 5/5 companies · 48 observations

Definition: Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

### Revenue — largest
1. Jubilant Agri & Consumer Products Ltd (JUBLCPL): ₹1.9K Cr
2. Sudeep Pharma Ltd (SUDEEPPHRM): ₹642 Cr
3. Chembond Chemicals Ltd (CHEMBONDCH): ₹347 Cr
4. Anlon Healthcare Ltd (AHCL): ₹173 Cr
5. Innovassynth Technologies (India) Ltd (533315): ₹0 Cr — older report

### Revenue growth — fastest growers
1. Anlon Healthcare Ltd (AHCL): 43%
2. Jubilant Agri & Consumer Products Ltd (JUBLCPL): 21%
3. Sudeep Pharma Ltd (SUDEEPPHRM): 20%
4. Chembond Chemicals Ltd (CHEMBONDCH): 18%

### 20-quarter Revenue history
- 533315: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 ₹0 Cr | Dec 2022 ₹0 Cr | Mar 2023 ₹0 Cr | Jun 2023 ₹0 Cr | Sep 2023 ₹0 Cr | Dec 2023 ₹0 Cr | Mar 2024 ₹0 Cr | Jun 2024 ₹0 Cr | Sep 2024 ₹0 Cr | Dec 2024 ₹0 Cr | Mar 2025 ₹0 Cr | Jun 2025 ₹0 Cr | Sep 2025 ₹0 Cr | Dec 2025 — | Mar 2026 — | Jun 2026 —
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹114 Cr | Sep 2024 ₹149 Cr | Dec 2024 ₹116 Cr | Mar 2025 ₹158 Cr | Jun 2025 ₹125 Cr | Sep 2025 ₹163 Cr | Dec 2025 ₹172 Cr | Mar 2026 ₹182 Cr | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 ₹293 Cr | Mar 2024 ₹300 Cr | Jun 2024 ₹358 Cr | Sep 2024 ₹407 Cr | Dec 2024 ₹398 Cr | Mar 2025 ₹398 Cr | Jun 2025 ₹442 Cr | Sep 2025 ₹513 Cr | Dec 2025 ₹451 Cr | Mar 2026 ₹485 Cr | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹38 Cr | Sep 2024 ₹24 Cr | Dec 2024 ₹9 Cr | Mar 2025 ₹49 Cr | Jun 2025 ₹33 Cr | Sep 2025 ₹52 Cr | Dec 2025 ₹36 Cr | Mar 2026 ₹51 Cr | Jun 2026 —
- CHEMBONDCH: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹64 Cr | Sep 2024 ₹75 Cr | Dec 2024 ₹75 Cr | Mar 2025 ₹78 Cr | Jun 2025 ₹65 Cr | Sep 2025 ₹73 Cr | Dec 2025 ₹86 Cr | Mar 2026 ₹101 Cr | Jun 2026 ₹86 Cr

### 20-quarter Revenue growth history
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 9.7% | Sep 2025 9.4% | Dec 2025 48% | Mar 2026 15% | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 36% | Mar 2025 33% | Jun 2025 23% | Sep 2025 26% | Dec 2025 13% | Mar 2026 22% | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 -12% | Sep 2025 116% | Dec 2025 285% | Mar 2026 4.1% | Jun 2026 —
- CHEMBONDCH: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 1.6% | Sep 2025 -2.7% | Dec 2025 15% | Mar 2026 30% | Jun 2026 32%

## Operating Economics & Margin Trend

What the numbers say: Sudeep Pharma Ltd leads opm at 34%; Chembond Chemicals Ltd leads margin change at +0.2 percentage points.

Investor read: Sudeep Pharma Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Evidence: Sudeep Pharma Ltd · 34% | 13.3% versus #2 · Anlon Healthcare Ltd | 1/4 recent comparable periods | 4/5 companies · 35 observations

Definition: Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

### OPM — highest
1. Sudeep Pharma Ltd (SUDEEPPHRM): 34%
2. Anlon Healthcare Ltd (AHCL): 30%
3. Chembond Chemicals Ltd (CHEMBONDCH): 13%
4. Jubilant Agri & Consumer Products Ltd (JUBLCPL): 7.0%

### Margin change — fastest expanders
1. Chembond Chemicals Ltd (CHEMBONDCH): +0.2 pp
2. Jubilant Agri & Consumer Products Ltd (JUBLCPL): 0.0 pp
3. Sudeep Pharma Ltd (SUDEEPPHRM): −3.0 pp
4. Anlon Healthcare Ltd (AHCL): −5.0 pp

### 20-quarter OPM history
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 38% | Sep 2024 43% | Dec 2024 34% | Mar 2025 37% | Jun 2025 35% | Sep 2025 34% | Dec 2025 35% | Mar 2026 34% | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 9.0% | Mar 2024 7.0% | Jun 2024 12% | Sep 2024 10% | Dec 2024 9.0% | Mar 2025 7.0% | Jun 2025 14% | Sep 2025 12% | Dec 2025 8.0% | Mar 2026 7.0% | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 18% | Sep 2024 31% | Dec 2024 6.2% | Mar 2025 35% | Jun 2025 19% | Sep 2025 26% | Dec 2025 35% | Mar 2026 30% | Jun 2026 —
- CHEMBONDCH: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 11% | Sep 2024 11% | Dec 2024 19% | Mar 2025 16% | Jun 2025 13% | Sep 2025 15% | Dec 2025 14% | Mar 2026 16% | Jun 2026 13%

### 20-quarter Margin change history
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 −2.9 pp | Sep 2025 −9.0 pp | Dec 2025 +1.0 pp | Mar 2026 −3.0 pp | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 0.0 pp | Mar 2025 0.0 pp | Jun 2025 +2.0 pp | Sep 2025 +2.0 pp | Dec 2025 −1.0 pp | Mar 2026 0.0 pp | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 +0.6 pp | Sep 2025 −4.8 pp | Dec 2025 +28.8 pp | Mar 2026 −5.0 pp | Jun 2026 —
- CHEMBONDCH: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 +1.5 pp | Sep 2025 +4.1 pp | Dec 2025 −4.9 pp | Mar 2026 −0.1 pp | Jun 2026 +0.2 pp

## Profit Scale & Acceleration

What the numbers say: Sudeep Pharma Ltd leads with ₹175 crore of TTM profit, 36.7% above Jubilant Agri & Consumer Products Ltd. Jubilant Agri & Consumer Products Ltd shows 45.5% growth from a ₹128 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

Investor read: Sudeep Pharma Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Evidence: Sudeep Pharma Ltd · ₹175 crore | 36.7% versus #2 · Jubilant Agri & Consumer Products Ltd | 2/4 recent comparable periods | 5/5 companies · 48 observations

Definition: Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

### Net profit — largest
1. Sudeep Pharma Ltd (SUDEEPPHRM): ₹175 Cr
2. Jubilant Agri & Consumer Products Ltd (JUBLCPL): ₹128 Cr
3. Chembond Chemicals Ltd (CHEMBONDCH): ₹38 Cr
4. Anlon Healthcare Ltd (AHCL): ₹29 Cr
5. Innovassynth Technologies (India) Ltd (533315): ₹-5 Cr — older report

### Profit growth — fastest growers
1. Jubilant Agri & Consumer Products Ltd (JUBLCPL): 46%
2. Anlon Healthcare Ltd (AHCL): 33%
3. Chembond Chemicals Ltd (CHEMBONDCH): 20%
4. Sudeep Pharma Ltd (SUDEEPPHRM): 13%

### 20-quarter Net profit history
- 533315: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 ₹-1 Cr | Dec 2022 ₹-4 Cr | Mar 2023 ₹4 Cr | Jun 2023 ₹-5 Cr | Sep 2023 ₹-1 Cr | Dec 2023 ₹-4 Cr | Mar 2024 ₹9 Cr | Jun 2024 ₹-6 Cr | Sep 2024 ₹-6 Cr | Dec 2024 ₹3 Cr | Mar 2025 ₹4 Cr | Jun 2025 ₹-7 Cr | Sep 2025 ₹-5 Cr | Dec 2025 — | Mar 2026 — | Jun 2026 —
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹33 Cr | Sep 2024 ₹49 Cr | Dec 2024 ₹29 Cr | Mar 2025 ₹44 Cr | Jun 2025 ₹31 Cr | Sep 2025 ₹47 Cr | Dec 2025 ₹48 Cr | Mar 2026 ₹49 Cr | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 ₹-21 Cr | Mar 2024 ₹22 Cr | Jun 2024 ₹26 Cr | Sep 2024 ₹25 Cr | Dec 2024 ₹21 Cr | Mar 2025 ₹16 Cr | Jun 2025 ₹44 Cr | Sep 2025 ₹42 Cr | Dec 2025 ₹22 Cr | Mar 2026 ₹20 Cr | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹5 Cr | Sep 2024 ₹3 Cr | Dec 2024 ₹-2 Cr | Mar 2025 ₹17 Cr | Jun 2025 ₹4 Cr | Sep 2025 ₹9 Cr | Dec 2025 ₹5 Cr | Mar 2026 ₹11 Cr | Jun 2026 —
- CHEMBONDCH: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹6 Cr | Sep 2024 ₹7 Cr | Dec 2024 ₹10 Cr | Mar 2025 ₹9 Cr | Jun 2025 ₹6 Cr | Sep 2025 ₹7 Cr | Dec 2025 ₹10 Cr | Mar 2026 ₹12 Cr | Jun 2026 ₹10 Cr

### 20-quarter Profit growth history
- 533315: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 121% | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 -57% | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 -6.1% | Sep 2025 -4.1% | Dec 2025 66% | Mar 2026 11% | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 -27% | Jun 2025 69% | Sep 2025 68% | Dec 2025 4.8% | Mar 2026 25% | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 -22% | Sep 2025 260% | Dec 2025 — | Mar 2026 -35% | Jun 2026 —
- CHEMBONDCH: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 12% | Sep 2025 4.5% | Dec 2025 -2.6% | Mar 2026 34% | Jun 2026 52%

## Capacity Spending & Returns On It

What the numbers say: Sudeep Pharma Ltd reports ₹14 crore of CAPEX; Sudeep Pharma Ltd has the highest covered intensity at 8.6%. Coverage is only 2 of 5 companies and 8 reported observations, so this is partial evidence—not a complete sector rank.

Investor read: Use the CAPEX rank as a diligence queue. Verify commissioning, utilization, cash conversion and post-investment ROCE before treating spend as value creation.

This conclusion weakens if: CAPEX rises without higher utilization, operating cash flow or incremental returns.

Evidence: Sudeep Pharma Ltd · ₹14 crore | null versus #2 · Anlon Healthcare Ltd | 6/6 recent comparable periods | 2/5 companies · 8 observations

Definition: CAPEX is cash spent on property, plant, equipment and other reported capital assets. CAPEX intensity divides that spend by revenue; high intensity is a reinvestment signal, not proof that the reinvestment will earn attractive returns.

### CAPEX — largest spenders
1. Sudeep Pharma Ltd (SUDEEPPHRM): ₹14 Cr
2. Anlon Healthcare Ltd (AHCL): ₹0 Cr

### CAPEX intensity — highest reinvestment intensity
1. Sudeep Pharma Ltd (SUDEEPPHRM): 8.6%
2. Anlon Healthcare Ltd (AHCL): 0.0%

### 20-quarter CAPEX history
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹14 Cr | Sep 2024 ₹14 Cr | Dec 2024 ₹16 Cr | Mar 2025 ₹20 Cr | Jun 2025 ₹15 Cr | Sep 2025 ₹14 Cr | Dec 2025 — | Mar 2026 — | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹0 Cr | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 ₹0 Cr | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —

### 20-quarter CAPEX intensity history
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 12% | Sep 2024 9.4% | Dec 2024 14% | Mar 2025 13% | Jun 2025 12% | Sep 2025 8.6% | Dec 2025 — | Mar 2026 — | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 0.0% | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 0.0% | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —

## Debt Load & Balance-Sheet Headroom

What the numbers say: Chembond Chemicals Ltd has the clearest covered balance-sheet capacity with ₹52 crore net cash and gross debt of ₹0 crore. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.

Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.

This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.

Evidence: Chembond Chemicals Ltd · ₹0 crore | 100% versus #2 · Innovassynth Technologies (India) Ltd | 8/8 recent comparable periods | 5/5 companies · 46 observations

Definition: Gross debt shows contractual borrowings. Net debt subtracts reported cash; a negative value means net cash. Lower debt can create capacity, but should be read against the scale and capital intensity of the business.

### Gross debt — lowest gross debt
1. Chembond Chemicals Ltd (CHEMBONDCH): ₹0 Cr
2. Innovassynth Technologies (India) Ltd (533315): ₹5 Cr — older report
3. Anlon Healthcare Ltd (AHCL): ₹44 Cr
4. Jubilant Agri & Consumer Products Ltd (JUBLCPL): ₹51 Cr
5. Sudeep Pharma Ltd (SUDEEPPHRM): ₹150 Cr

### Net debt — lowest net debt
1. Chembond Chemicals Ltd (CHEMBONDCH): ₹-52 Cr
2. Sudeep Pharma Ltd (SUDEEPPHRM): ₹35 Cr
3. Anlon Healthcare Ltd (AHCL): ₹40 Cr
4. Jubilant Agri & Consumer Products Ltd (JUBLCPL): ₹45 Cr

### 20-quarter Gross debt history
- 533315: Sep 2021 — | Dec 2021 — | Mar 2022 ₹3 Cr | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 ₹3 Cr | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 ₹4 Cr | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 ₹4 Cr | Jun 2025 — | Sep 2025 ₹5 Cr | Dec 2025 — | Mar 2026 — | Jun 2026 —
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 ₹84 Cr | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 ₹83 Cr | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 ₹78 Cr | Jun 2024 ₹79 Cr | Sep 2024 — | Dec 2024 ₹120 Cr | Mar 2025 ₹140 Cr | Jun 2025 ₹138 Cr | Sep 2025 ₹143 Cr | Dec 2025 ₹143 Cr | Mar 2026 ₹150 Cr | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 ₹163 Cr | Jun 2024 ₹162 Cr | Sep 2024 — | Dec 2024 — | Mar 2025 ₹78 Cr | Jun 2025 ₹77 Cr | Sep 2025 ₹41 Cr | Dec 2025 ₹41 Cr | Mar 2026 ₹51 Cr | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 ₹62 Cr | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 ₹70 Cr | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 ₹81 Cr | Jun 2024 ₹79 Cr | Sep 2024 ₹79 Cr | Dec 2024 — | Mar 2025 ₹67 Cr | Jun 2025 ₹58 Cr | Sep 2025 ₹58 Cr | Dec 2025 ₹58 Cr | Mar 2026 ₹44 Cr | Jun 2026 —
- CHEMBONDCH: Sep 2021 ₹3 Cr | Dec 2021 ₹3 Cr | Mar 2022 ₹2 Cr | Jun 2022 ₹2 Cr | Sep 2022 ₹6 Cr | Dec 2022 ₹6 Cr | Mar 2023 ₹7 Cr | Jun 2023 ₹7 Cr | Sep 2023 ₹9 Cr | Dec 2023 ₹9 Cr | Mar 2024 ₹0 Cr | Jun 2024 ₹7 Cr | Sep 2024 — | Dec 2024 — | Mar 2025 ₹0 Cr | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 ₹0 Cr | Jun 2026 —

### 20-quarter Net debt history
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹65 Cr | Sep 2024 — | Dec 2024 ₹87 Cr | Mar 2025 ₹86 Cr | Jun 2025 ₹80 Cr | Sep 2025 ₹75 Cr | Dec 2025 ₹75 Cr | Mar 2026 ₹35 Cr | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 ₹147 Cr | Jun 2024 ₹147 Cr | Sep 2024 — | Dec 2024 — | Mar 2025 ₹71 Cr | Jun 2025 ₹71 Cr | Sep 2025 ₹29 Cr | Dec 2025 ₹29 Cr | Mar 2026 ₹45 Cr | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 ₹76 Cr | Sep 2024 ₹76 Cr | Dec 2024 — | Mar 2025 ₹65 Cr | Jun 2025 ₹55 Cr | Sep 2025 ₹15 Cr | Dec 2025 ₹15 Cr | Mar 2026 ₹40 Cr | Jun 2026 —
- CHEMBONDCH: Sep 2021 ₹-59 Cr | Dec 2021 ₹-59 Cr | Mar 2022 ₹-53 Cr | Jun 2022 ₹-63 Cr | Sep 2022 ₹-50 Cr | Dec 2022 ₹-50 Cr | Mar 2023 ₹-30 Cr | Jun 2023 ₹-30 Cr | Sep 2023 ₹-61 Cr | Dec 2023 ₹-61 Cr | Mar 2024 — | Jun 2024 ₹-52 Cr | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —

## Return On Capital Employed

What the numbers say: Jubilant Agri & Consumer Products Ltd leads ROCE at 39.9%, 11.7 percentage points above Sudeep Pharma Ltd. Jubilant Agri & Consumer Products Ltd has the strongest latest improvement at +0.1 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

Investor read: Jubilant Agri & Consumer Products Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

Evidence: Jubilant Agri & Consumer Products Ltd · 39.9% | 41.5% versus #2 · Sudeep Pharma Ltd | 2/2 recent comparable periods | 5/5 companies · 30 observations

Definition: ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

### ROCE — highest
1. Jubilant Agri & Consumer Products Ltd (JUBLCPL): 40%
2. Sudeep Pharma Ltd (SUDEEPPHRM): 28%
3. Chembond Chemicals Ltd (CHEMBONDCH): 24%
4. Anlon Healthcare Ltd (AHCL): 21%
5. Innovassynth Technologies (India) Ltd (533315): -9.2% — older report

### ROCE change — fastest improvers
1. Jubilant Agri & Consumer Products Ltd (JUBLCPL): +0.1 pp
2. Chembond Chemicals Ltd (CHEMBONDCH): −2.2 pp
3. Anlon Healthcare Ltd (AHCL): −7.8 pp
4. Innovassynth Technologies (India) Ltd (533315): −7.9 pp — older report
5. Sudeep Pharma Ltd (SUDEEPPHRM): −15.0 pp

### 20-quarter ROCE history
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 30% | Mar 2025 36% | Jun 2025 26% | Sep 2025 24% | Dec 2025 37% | Mar 2026 21% | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 15% | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 35% | Jun 2025 46% | Sep 2025 38% | Dec 2025 47% | Mar 2026 35% | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 7.9% | Sep 2024 — | Dec 2024 — | Mar 2025 25% | Jun 2025 24% | Sep 2025 15% | Dec 2025 29% | Mar 2026 17% | Jun 2026 —
- CHEMBONDCH: Sep 2021 5.6% | Dec 2021 — | Mar 2022 4.9% | Jun 2022 — | Sep 2022 5.6% | Dec 2022 — | Mar 2023 10% | Jun 2023 — | Sep 2023 13% | Dec 2023 — | Mar 2024 27% | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 19% | Jun 2025 27% | Sep 2025 19% | Dec 2025 26% | Mar 2026 21% | Jun 2026 25%

### 20-quarter ROCE change history
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 +6.7 pp | Mar 2026 −15.0 pp | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 +19.7 pp | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 +0.1 pp | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 +16.0 pp | Sep 2025 — | Dec 2025 — | Mar 2026 −7.8 pp | Jun 2026 —
- CHEMBONDCH: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 0.0 pp | Dec 2022 — | Mar 2023 +5.2 pp | Jun 2023 — | Sep 2023 +6.9 pp | Dec 2023 — | Mar 2024 +16.8 pp | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 −7.7 pp | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 +1.8 pp | Jun 2026 −2.2 pp

## Valuation Against Growth & Quality

What the numbers say: Jubilant Agri & Consumer Products Ltd has the lowest comparable Guarded PEG at 0.79×, 83.4% below Sudeep Pharma Ltd. Only 2 of 5 companies pass the guard, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

Evidence: Jubilant Agri & Consumer Products Ltd · 0.79× | 83.4% versus #2 · Sudeep Pharma Ltd | 0/5 recent comparable periods | 2/5 companies · 2 observations

Definition: PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data sources reconciled. A missing PEG is more honest than a low-base fiction.

### Guarded PEG — lowest PEG
1. Jubilant Agri & Consumer Products Ltd (JUBLCPL): 0.8
2. Sudeep Pharma Ltd (SUDEEPPHRM): 4.8

### P/E — lowest P/E
1. Chembond Chemicals Ltd (CHEMBONDCH): 17.4
2. Jubilant Agri & Consumer Products Ltd (JUBLCPL): 21.5
3. Anlon Healthcare Ltd (AHCL): 28.0
4. Sudeep Pharma Ltd (SUDEEPPHRM): 53.9

### 20-quarter Guarded PEG history
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 4.8 | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 0.8 | Jun 2026 —

### 20-quarter P/E history
- 533315: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 63.0 | Sep 2022 56.3 | Dec 2022 1,824.0 | Mar 2023 1,837.0 | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 165.1 | Jun 2025 173.1 | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 42.1 | Mar 2026 35.6 | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 21.6 | Jun 2025 29.3 | Sep 2025 36.3 | Dec 2025 27.3 | Mar 2026 18.5 | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 25.8 | Dec 2025 23.2 | Mar 2026 20.8 | Jun 2026 —
- CHEMBONDCH: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 19.3 | Dec 2025 19.7 | Mar 2026 8.2 | Jun 2026 16.7

## Enterprise Value & Book Value

What the numbers say: Chembond Chemicals Ltd leads both ev/ebitda at 10.9× and p/bv at 3.21×.

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.

Evidence: Chembond Chemicals Ltd · 10.9× | 10.7% versus #2 · Jubilant Agri & Consumer Products Ltd | 0/4 recent comparable periods | 4/5 companies · 18 observations

Definition: EV/EBITDA includes debt in enterprise value and is useful across different capital structures. P/BV prices the company against its own book. Both are market multiples on reported figures, not intrinsic-value estimates and not forecasts.

### EV/EBITDA — lowest EV/EBITDA
1. Chembond Chemicals Ltd (CHEMBONDCH): 10.9
2. Jubilant Agri & Consumer Products Ltd (JUBLCPL): 12.2
3. Anlon Healthcare Ltd (AHCL): 12.7
4. Sudeep Pharma Ltd (SUDEEPPHRM): 27.7

### P/BV — lowest P/BV
1. Chembond Chemicals Ltd (CHEMBONDCH): 3.2
2. Anlon Healthcare Ltd (AHCL): 3.5
3. Jubilant Agri & Consumer Products Ltd (JUBLCPL): 6.1
4. Sudeep Pharma Ltd (SUDEEPPHRM): 10.6
5. Innovassynth Technologies (India) Ltd (533315): 15.1 — older report

### 20-quarter EV/EBITDA history
- 533315: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 53.8 | Sep 2022 48.4 | Dec 2022 185.8 | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 179.8 | Jun 2025 — | Sep 2025 — | Dec 2025 — | Mar 2026 — | Jun 2026 —
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 34.2 | Mar 2026 27.7 | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 18.8 | Jun 2025 18.0 | Sep 2025 21.3 | Dec 2025 17.9 | Mar 2026 12.2 | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 20.1 | Dec 2025 16.6 | Mar 2026 12.7 | Jun 2026 —
- CHEMBONDCH: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 8.8 | Dec 2025 8.2 | Mar 2026 5.3 | Jun 2026 10.9

### 20-quarter P/BV history
- 533315: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 2.1 | Sep 2022 1.9 | Dec 2022 1.5 | Mar 2023 1.2 | Jun 2023 1.6 | Sep 2023 2.0 | Dec 2023 1.9 | Mar 2024 2.2 | Jun 2024 2.1 | Sep 2024 6.4 | Dec 2024 8.6 | Mar 2025 7.0 | Jun 2025 4.7 | Sep 2025 6.7 | Dec 2025 — | Mar 2026 — | Jun 2026 —
- SUDEEPPHRM: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 — | Dec 2025 9.2 | Mar 2026 9.2 | Jun 2026 —
- JUBLCPL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 5.8 | Jun 2025 7.9 | Sep 2025 10.8 | Dec 2025 8.1 | Mar 2026 5.6 | Jun 2026 —
- AHCL: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 3.3 | Dec 2025 3.7 | Mar 2026 2.3 | Jun 2026 —
- CHEMBONDCH: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 2.4 | Dec 2025 2.2 | Mar 2026 1.6 | Jun 2026 2.8

## Market action

Jubilant Agri & Consumer Products Ltd has the strongest one-year price move in Chemicals - Speciality at -5.9%. Innovassynth Technologies (India) Ltd leads on Mansfield relative strength against NIFTY at +62.6%. 2 of 3 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-24.

### Strongest one-year price performers
1. Jubilant Agri & Consumer Products Ltd (JUBLCPL): -5.9%

### Strongest relative strength versus NIFTY 500
1. Innovassynth Technologies (India) Ltd (533315): 63%
2. Chembond Chemicals Ltd (CHEMBONDCH): 47%
3. Jubilant Agri & Consumer Products Ltd (JUBLCPL): -12%

## What can make this comparison misleading?
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
- 2 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
- Thin comparisons: Capital expenditure, Valuation have fewer than three usable current readings.

## Every company
- Sudeep Pharma Ltd (SUDEEPPHRM) — market value ₹9.3K Cr; latest fundamentals Mar 2026
- Jubilant Agri & Consumer Products Ltd (JUBLCPL) — market value ₹2.8K Cr; latest fundamentals Mar 2026
- Innovassynth Technologies (India) Ltd (533315) — market value ₹1.2K Cr; latest fundamentals Sep 2025
- Anlon Healthcare Ltd (AHCL) — market value ₹798 Cr; latest fundamentals Mar 2026; includes UNVERIFIED second-feed figures
- Chembond Chemicals Ltd (CHEMBONDCH) — market value ₹666 Cr; latest fundamentals Jun 2026; includes UNVERIFIED second-feed figures

## Source standing of each company

Cross-checked: 2. Unverified: 3. Withheld: 0. Graded companies: 5.

2 of 5 companies draw at least one figure from a second data feed that could not be cross-checked against the primary source, because the two do not share enough reported history to compare. Those figures are marked unverified wherever they appear.

- UNVERIFIED | AHCL | Anlon Healthcare Ltd | too little overlapping reported history to cross-check the second feed
- UNVERIFIED | CHEMBONDCH | Chembond Chemicals Ltd | too little overlapping reported history to cross-check the second feed

## Methodology and freshness

Fundamentals through Jun 2026; prices through 2026-07-24.
Up to 20 quarters per company. Reported history is normalized to Indian rupees crore. Missing values are not interpolated. Derived metrics are calculated only when their inputs are comparable.

## Frequently asked questions

### What is the Nifty Chemicals - Speciality index?

The Nifty Chemicals - Speciality index tracks India's listed Chemicals - Speciality companies as a single basket. This page follows the same 5 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Chemicals - Speciality sector rather than to its largest constituent. Figures are as of Jun 2026.

### Which are the best Chemicals - Speciality stocks in India?

Ranked by this page's four-factor score, Chembond Chemicals Ltd places first among 5 listed Chemicals - Speciality companies, followed by Jubilant Agri & Consumer Products Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

### How many Chemicals - Speciality stocks are listed in India?

This comparison covers 5 listed Chemicals - Speciality companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

### Which Chemicals - Speciality company is the biggest?

Jubilant Agri & Consumer Products Ltd is the largest, with trailing-twelve-month revenue of ₹1,891 crore, ahead of Sudeep Pharma Ltd at ₹642 crore. That covers 5 of 5 companies with comparable reporting through Mar 2026.

### Which Chemicals - Speciality company is growing fastest?

Anlon Healthcare Ltd has the fastest revenue growth at 43.3% year on year, across 4 of 5 comparable companies. Fast growth off a small base is not the same as proven scale — check whether the rate holds across several quarters on the chart above before treating it as a trend.

### Which Chemicals - Speciality company has the best profit margins?

Sudeep Pharma Ltd has the highest operating margin at 34%, from 4 of 5 comparable companies. Chembond Chemicals Ltd shows the biggest recent improvement, at +0.2 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

### Which Chemicals - Speciality company makes the most profit?

Sudeep Pharma Ltd earns the most, at ₹175 crore of trailing-twelve-month net profit, from 5 of 5 comparable companies. Jubilant Agri & Consumer Products Ltd has the fastest profit growth at 45.5%, though growth off a small or recovering profit base overstates how much has actually changed.

### Which Chemicals - Speciality company earns the highest return on capital?

Jubilant Agri & Consumer Products Ltd leads on return on capital employed at 39.9%, across 5 of 5 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

### Which Chemicals - Speciality stock is the cheapest?

On guarded PEG — where a LOWER number is cheaper — Jubilant Agri & Consumer Products Ltd screens cheapest at 0.79×. Only 2 of 5 companies pass the comparability guard, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

### Which Chemicals - Speciality company has the strongest balance sheet?

Chembond Chemicals Ltd carries the lowest comparable gross debt at ₹0 crore, from 5 of 5 companies. Absolute rupee debt alone does not settle it, because company scale differs — net debt and debt-to-equity in the chart above carry more information, and a very low-debt balance sheet can also mean under-investment.

### Is the Chemicals - Speciality sector beating the market?

Chemicals - Speciality has outperformed NIFTY 500 by 74.2% over the last 52 weeks and 25% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 2 of 3 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

### Which Chemicals - Speciality stock has the strongest price momentum?

Innovassynth Technologies (India) Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

### Which Chemicals - Speciality company scores highest for research priority?

Chembond Chemicals Ltd scores 62.2 out of 100 with 62% evidence confidence, from 22.7 points on growth and earnings, 17 on capital efficiency, 10 on valuation and 12.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

### How many Chemicals - Speciality companies does this comparison cover, and over what period?

It compares 5 listed companies over up to 20 reported quarters of fundamentals and 7 fiscal years of capital allocation, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

### What is the total market cap of the Chemicals - Speciality sector?

The 5 Chemicals - Speciality companies on this page carry ₹14,826 crore of combined market value. Sudeep Pharma Ltd is the largest at ₹9,320 crore, about 63% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-07-29.

### How is the Chemicals - Speciality sector performing?

2 of the 3 covered Chemicals - Speciality companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 74.2% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-07-29.

### Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

### Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

Narrative sector analysis: https://www.sectoralpha.in/sectors/chemicals-speciality